CLINICAL TRIAL / NCT02939183

Inclusion criteria - Subject must have a pathologically documented, definitively diagnosed, multiple myeloma relapsed, or refractory progressive disease after at least 2 lines of therapy for multiple myeloma. Prior therapeutic treatment or regimens must include a proteasome inhibitor and lenalidomide. - Subject must be willing and able to undergo bone marrow aspirate per protocol (with or without bone marrow biopsy per institutional guidelines). - Measurable disease (assessed within 28 days prior to day 1) - Eastern Cooperative Oncology Group (ECOG) performance status of <= 2. - Other Inclusion Criteria May Apply Exclusion Criteria - Currently receiving treatment in another investigational device or drug study, or less than 28 days or 5 half-lives whichever is shorter since ending treatment on another investigational device or drug study(s). - Previously received an allogeneic stem cell transplant and the occurrence of one or more of the following: received the transplant within 6 months prior to study day 1;received immunosuppressive therapy within the last 3 months prior to study day 1;having signs or symptoms of acute or chronic graft-versus-host disease. - Autologous stem cell transplant < 90 days prior to study day 1. - Multiple myeloma with IgM subtype. - POEMs syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes). - Plasma cell leukemia (> 2.0 X109/L circulating plasma cells by standard differential). - Waldenstrom's macroglobulinemia. - Other Exclusion Criteria May Apply